InflaRx director Brudnick reports initial IFRX holdings
InflaRx N.V. director Richard Brudnick has filed an initial ownership report showing existing equity holdings.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
InflaRx N.V. director Richard Brudnick has filed an initial ownership report showing existing equity holdings. He directly holds 50,000 Ordinary Shares and multiple stock options over additional Ordinary Shares with exercise prices between $1.17 and $2.41 per share, expiring from 2029 through 2036. Most option grants are already fully vested and exercisable, while a January 2026 grant for 30,000 shares will vest in four equal quarterly installments of 7,500 shares, subject to continued service.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Holding | Stock Option (Right to Buy) | -- | -- | -- |
| Holding | Stock Option (Right to Buy) | -- | -- | -- |
| Holding | Stock Option (Right to Buy) | -- | -- | -- |
| Holding | Stock Option (Right to Buy) | -- | -- | -- |
| Holding | Stock Option (Right to Buy) | -- | -- | -- |
| Holding | Stock Option (Right to Buy) | -- | -- | -- |
| Holding | Stock Option (Right to Buy) | -- | -- | -- |
| Holding | Stock Option (Right to Buy) | -- | -- | -- |
| Holding | Ordinary Shares | -- | -- | -- |
Footnotes (8)
- F1. This option was granted on February 4, 2019 and is fully vested and exercisable as of the date hereof.
- F2. This option was granted on January 4, 2021 and is fully vested and exercisable as of the date hereof.
- F3. This option was granted on July 2, 2021 and is fully vested and exercisable as of the date hereof.
- F4. This option was granted on January 12, 2022 and is fully vested and exercisable as of the date hereof.
- F5. This option was granted on January 24, 2023 and is fully vested and exercisable as of the date hereof.
- F6. This option was granted on January 5, 2024 and is fully vested and exercisable as of the date hereof.
- F7. This option was granted on January 3, 2025 and is fully vested and exercisable as of the date hereof.
- F8. This option was granted on January 6, 2026 and will vest and become exercisable in four equal installments of 7,500 shares on each quarterly anniversary of such grant date, subject to continued service through such dates.
AI-generated analysis. How Rhea-AI works. Not financial advice.
